Resverlogix Corp. (RVXCF)
OTCMKTS · Delayed Price · Currency is USD
0.0700
+0.0258 (58.37%)
Jul 16, 2025, 4:00 PM EDT
Resverlogix Company Description
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses.
The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions.
It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.
Contact Details
Address: 4820 Richard Road SW Calgary, Alberta T3E 6L1 Canada | |
| Phone | 403 254 9252 |
| Website | resverlogix.com |
Stock Details
| Ticker Symbol | RVXCF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | CA76128M1086 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Donald J. McCaffrey | Co-Founder, Chairman, President, Chief Executive Officer and Secretary |
| Aaron Bradley Cann C.A., CPA, CBV | Chief Financial Officer |
| Dr. Ewelina Kulikowski Ph.D. | Chief Scientific Officer |
| Dr. Michael Sweeney M.D. | Senior Vice President of Clinical Development |